Company Profile
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
Latest News
| Sector | Healthcare |
| Industry | Biotechnology |
| Website | https://www.zealandpharma.com |
| Audit Risk | 9 |
| Board Risk | 1 |
| Overall Risk | 4 |
| Market Cap | 20.22B |
| Trailing P/E | 3.29 |
| Forward P/E | 37.56 |
| Trailing Annual Div. Rate | 0 |
| Trailing Annual Div. Yield | 0.00% |
| Trailing EPS | 89.38 |
| Forward EPS | 7.82 |
| Book Value | 204.77 |
| Price-to-Book | 1.43 |
| Enterprise-to-Revenue | 0.71 |
| Enterprise-to-EBITDA | 0.97 |
| Earnings Date | 08/13/2026 |
| Earnings Call Date | 05/07/2026 |
| Earnings Average | 19.98 |
| Earnings Low | -0.08 |
| Earnings High | 53.6 |
| Revenue Average | 2.07B |
| Revenue Low | 800.00M |
| Revenue High | 4.58B |